Skip to main content

Stephen Turner, Charles Cantor, Erik Wallden, Peter Tattle, Patrick Zenner

Premium

Stephen Turner, 58, the co-founder, chairman, and chief executive officer of Frederick, Md.-based Clinomics, will become a non-executive director of Cambridge, UK-based Cytomyx, upon the completion of the acquisition of Clinomics by Cytomyx, the company said. Turner will oversee US operations and business development in the US market.


Charles Cantor will join the scien-tific advisory board of St. Joseph, Mich.-based GeneGo, a bioinformatics firm. Cantor is currently chief scientific officer and a board member of Sequenom. He is also director of the Center for Advanced Biotechnology at Boston University. Cantor has held positions at Columbia University and the University of California at Berkeley, and was director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. In 2002, he founded SelectX Pharmaceuticals.


Erik Wallden will head marketing and business development for Biacore International from Neuchatel, Switzerland, as executive vice president, taking a new position that reports to the president and chief executive officer of the Uppsala, Sweden-based company. Wallden will begin work on Jan. 19. Wallden previously was president and CEO of Pyrosequencing, a position he held since 1997. Previously, he held various R&D and marketing positions within Pharmacia Biotechnology (today Amersham Biosciences), before he was appointed vice president worldwide marketing, sales and support at Pharmacia Biosensor, whose name was changed to Biacore in conjunction with the company’s initial public offering in 1989.


Peter Tattle joins the board of directors of Genta, a Berkeley Heights, NJ-based company. Tattle was previously chairman for pharmaceuticals in the Americas for Johnson & Johnson before retiring in 2001. Tattle currently serves on the boards of Xanthus Life Sciences, DFB Pharmaceuticals, Catalina Marketing, and the Cancer Institute of New Jersey. He replaces Patrick Zenner, who resigned from Genta’s board. Genta is developing RNA and DNA-based medicines.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.